Cormedix Inc
CRMD
Company Profile
Business description
Cormedix Inc is a biopharmaceutical company focused on developing and commercializing therapeutic products for life-threatening diseases and conditions. The Company's focus is on the commercialization of its product, DefenCath, in the United States and other key markets. The group currently operates in a single segment, Drug Product, located in a single geographic location, the United States.
Contact
389 Interpace Parkway
Suite 450
ParsippanyNJ07054
USAT: +1 908 517-9500
Sector
Healthcare
Stock type
Defensive
Industry
Biotechnology
Fiscal Year End
31 December 2026
Employees
191
Stocks News & Analysis
stocks
Sales shine but broader macro outlook darkens for this ASX share
US stores are struggling, but our investment thesis hinges on the Australian rollout.
stocks
Chart of the Week: US equity market trading at an attractive discount
The latest from our Chief US Market Strategist.
stocks
Undervalued ASX share retains wide moat rating despite regulatory pressures
Proposed price regulation impacts our fair value.
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 9,168.90 | 43.80 | 0.48% |
| CAC 40 | 8,205.71 | 58.16 | -0.70% |
| DAX 40 | 23,744.10 | 336.53 | -1.40% |
| Dow JONES (US) | 47,769.34 | 140.58 | -0.29% |
| FTSE 100 | 10,583.05 | 25.83 | -0.24% |
| HKSE | 25,752.40 | 140.62 | -0.54% |
| NASDAQ | 22,595.00 | 39.99 | -0.18% |
| Nikkei 225 | 55,895.32 | 413.10 | -0.73% |
| NZX 50 Index | 13,273.81 | 19.87 | 0.15% |
| S&P 500 | 6,772.69 | 10.12 | -0.15% |
| S&P/ASX 200 | 8,973.20 | 57.80 | 0.65% |
| SSE Composite Index | 3,966.17 | 28.83 | -0.72% |